Sunitinib Malate

For research use only.

Licensed by Pfizer Catalog No.S1042

66 publications

Sunitinib Malate Chemical Structure

Molecular Weight(MW): 532.56

Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit. Sunitinib Malate effectively inhibits autophosphorylation of Ire1α. Sunitinib Malate increases both death receptor and mitochondrial-dependent apoptosis.

Size Price Stock Quantity  
10mM (1mL in DMSO) RMB 1554.98 In stock
RMB 466.83 In stock
RMB 780.34 In stock
RMB 1204.22 In stock
RMB 2104.83 In stock
RMB 3652.98 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Sunitinib Malate has been cited by 66 publications

Purity & Quality Control

Choose Selective PDGFR Inhibitors

Biological Activity

Description Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit. Sunitinib Malate effectively inhibits autophosphorylation of Ire1α. Sunitinib Malate increases both death receptor and mitochondrial-dependent apoptosis.
Targets
Kit [1]
(Cell-free assay)
FLT3 [1]
(Cell-free assay)
PDGFRβ [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
2 nM 80 nM
In vitro

Sunitinib also potently inhibits Kit and FLT-3. [1] Sunitinib is a potent ATP-competitive inhibitor of VEGFR2 (Flk1) and PDGFRβ with Ki of 9 nM and 8 nM, respectively, displaying >10-fold higher selectivity for VEGFR2 and PDGFR than FGFR-1, EGFR, Cdk2, Met, IGFR-1, Abl, and src. In serum-starved NIH-3T3 cells expressing VEGFR2 or PDGFRβ, Sunitinib inhibits VEGF-dependent VEGFR2 phosphorylation and PDGF-dependent PDGFRβ phosphorylation with IC50 of 10 nM and 10 nM, respectively. Sunitinib inhibits VEGF-induced proliferation of serum-starved HUVECs with IC50 of 40 nM, and inhibits PDGF-induced proliferation of NIH-3T3 cells overexpressing PDGFRβ or PDGFRα with IC50 of 39 nM and 69 nM, respectively. [2] Sunitinib inhibits phosphorylation of wild-type FLT3, FLT3-ITD, and FLT3-Asp835 with IC50 of 250 nM, 50 nM, and 30 nM, respectively. Sunitinib inhibits the proliferation of MV4;11 and OC1-AML5 cells with IC50 of 8 nM and 14 nM, respectively, and induces apoptosis in a dose-dependent manner. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
3T3 MYjLbY5ie2ViQYPzZZk> NGjSbnlKdmirYnn0bY9vKG:oIGDES2YucW6mdXPl[EBDemSXIHnuZ49zeG:{YYTpc44hf2m2aDDJR|UxKG:oIECuNFA4KM7:TR?= MXSxNlY1PjBzOR?=
3T3 M4f5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkX1TY5pcWKrdHnvckBw\iCSbHH0[YxmfC2mZYLpeoVlKGe{b4f0bEBn[WO2b4KgbY5lfWOnZDCzWFMh[2WubDDwdo9tcW[ncnH0bY9vKHerdHigTWM2OCCxZjCwMlAyKM7:TR?= NHTLRnkyOjZ2NkCxPS=>
3T3 MXLGeY5kfGmxbjDBd5NigQ>? M1rafGlvcGmkaYTpc44hd2ZiVnHzZ5Vt[XJiZX7kc5Rp\WyrYXyg[5Jwf3SqIH\hZ5RweiC{ZXPldJRweiC5aYToJGlEPTBib3[gNE4xPSEQvF2= NWHXRXFGOTJ4NE[wNVk>
3T3 MnezT4lv[XOnIFHzd4F6 MkP5NlAhdWmw NFHvfZpFVVOR MmfzR4VtdHWuYYKgbY5pcWKrdHnvckBw\iCYRVfGJIlv\HWlZXSgbJVu[W5iS1TSJJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yMkKg{txO NGX0e48yPjF4MkCwPC=>
NIH3T3 MmnHT4lv[XOnIFHzd4F6 MXuyNEBucW5? NF\ZS2RFVVOR NVjScFZNcW6qaXLpeEBpfW2jbjDLSHIhc2mwYYPlJIV5eHKnc4Pl[EB4cXSqIFnDOVAhd2ZiMD6wNVgh|ryP M3LM[FE3OTZ{MEC4
A549 MXLGeY5kfGmxbjDBd5NigQ>? MXPEUXNQ MYXJcohq[mm2aX;uJI9nKGNvTXX0JIRmeGWwZHXueEBJT0ZvaX7keYNm\CCqdX3hckBCPTR7IHPlcIwhdWmpcnH0bY9vKHerdHigTWM2OCCxZjCyJO69VQ>? MnjRNVg1OzRzNEW=
DU145 NYi3cXJlTnWwY4Tpc44hSXO|YYm= MVPEUXNQ NIHEeFBKdmirYnn0bY9vKG:oIHOtUYV1KGSncHXu[IVvfCCKR1[tbY5lfWOnZDDoeY1idiCGVUG0OUBk\WyuIIPjZZR1\XKrbnege4l1cCCLQ{WwJI9nKDFyIN88US=> NXrtfYRwOTh2M{SxOFU>
KB3-1 MkHlR5l1d3SxeHnjJGF{e2G7 MYS3NkBp NXHV[Ho5TE2VTx?= NFrxSYlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRNWeyLX7l[4F1cX[nIFvCMVMuOSClZXzsd{B4cXSqIFnDOVAhd2ZiMj6zJO69VQ>? Mm\oNVk{QTd|MkK=
KBV1 NEXURXFEgXSxdH;4bYMhSXO|YYm= MUG3NkBp M4\MSGROW09? MWnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQMYdtgWOxcILveIVqdi2neIDy[ZN{cW6pIFvCWlEh[2WubIOge4l1cCCLQ{WwJI9nKDRwMTFOwG0> MXexPVM6PzN{Mh?=
A375 NWqxUm9KS3m2b4TvfIlkKEG|c3H5 NGX4dJo4OiCq MkCwSG1UVw>? MX;JR|UxRTVwNDFOwG0> MonsNVk3PTR2MEi=
RS4-11 NFf5SoVHfW6ldHnvckBCe3OjeR?= MWeyJIg> M3rCRWlvcGmkaYTpc44hd2ZiRlzUN{BifXSxcHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlAxQTlizszN NF;XU2gyQTZ3NESwPC=>
RS4-11 NY\UV2J7TnWwY4Tpc44hSXO|YYm= MXiyJIg> M3XpbGlvcGmkaYTpc44hd2ZiRlzUN{BKXERibYX0ZY51KGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvODN2IN88US=> M4D3b|E6PjV2NEC4
Sf9 NFfKdHVMcW6jc3WgRZN{[Xl? NUftTox4OzBibXnu NE\WNGpKdmirYnn0bY9vKG:oIFfTWE11[WepZXSgWmVITlJiZYjwdoV{e2WmIIfpeIghUUN3MDDv[kAxNjF6NTFOwG0> NYL6W2FIOTl6NUSwOVE>
Ba/F3 NIL1UplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXS3NkBp MlGzTWM2OD1zLkKg{txO MonCNlAyOTdyMES=
BaPTC2 M{jwVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDic2hUPzJiaB?= MWLJR|UxRTBwMkKg{txO M{DZVlIxOTF5MEC0
Sf9 M3jYWWZ2dmO2aX;uJGF{e2G7 MUSxJIg> NXzMOJlzTE2VTx?= MWLJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KEircz30ZYdo\WRiUlXUJIV5eHKnc4Pl[EB4cXSqIFnDOVAhd2ZiMT6zJO69VQ>? M13nSVIxOTF5MEC0
H4 NGXlZYREgXSxdH;4bYMhSXO|YYm= MUWxNEDPxE1? Mmi3WI95cWOrdImgbY4hcHWvYX6gTFQh[2WubIO= M3\ybFIxOzVyOEC2
SF-539 MXLLbY5ie2ViQYPzZZk> MUOzN|Mh|ryP NUH4ZnlSPjBibXnu NU\CV2hzTE2VTx?= MWDJcohq[mm2aX;uJI9nKFCGR1\SZoV1[SCyaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIEGyMlIh|ryP Mor4NlA1ODN5MEC=
U251 NIrJcIJMcW6jc3WgRZN{[Xl? MVGzN|Mh|ryP M1r4RlYxKG2rbh?= M{DxeWROW09? M{DrT2lvcGmkaYTpc44hd2ZiVlXHSnIzKHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMUiuPUDPxE1? MnjxNlA1ODN5MEC=
A431 MVPLbY5ie2ViQYPzZZk> NHPMeIhKdmirYnn0bY9vKG:oIGDES2ZT[mW2YTDlfJBz\XO|ZXSge4l1cCCLQ{WwJI9nKDF{LkKg{txO MW[yNFU2QDB5Mh?=
A431 MkTXT4lv[XOnIFHzd4F6 NFqzcGtKdmirYnn0bY9vKG:oIG\FS2ZTOiCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFE5NjlizszN MnHkNlA2PThyN{K=
HepG2 MlXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIP0NHE4OiCq NYTHPFQ5UUN3ME2zMlgyKM7:TR?= NXTqUFlmOjB3N{C1NlY>
Kasumi-1 NEKzemJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkmwO|IhcA>? M{fnWGlEPTB;MD6wNVYh|ryP MnHzNlA2PzB3Mk[=
RS4-11 M1rCTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3MO|IhcA>? NEjQbYdKSzVyPUGg{txO NIPUWVEzODV5MEWyOi=>
THP1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYi3NkBp Mn;1TWM2OD1yLkWg{txO NX;pfYdnOjB3N{C1NlY>
Kasumi-1 M4noSGZ2dmO2aX;uJGF{e2G7 Mm\6TY5pcWKrdHnvckBw\iClLVvpeEBifXSxcHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlAyPSEQvF2= MmLvNlA5OzNyM{m=
A549 MmDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzxOoJpOTZiaB?= Mmj2RY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\Wyucx?= NHHXSJYzOTR3MES2Ny=>
HL60 M3KwOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfINVYhcA>? NV\EcGRHSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gTGw3OCClZXzsdy=> MoTvNlE1PTB2NkO=
HUVEC M3TZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWCxOkBp MW\Jcohq[mm2aX;uJI9nKF[HR1[tbY5lfWOnZDDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDJwN{Wg{txO MUiyNVQ2ODR4Mx?=
HUVEC NIO3Zo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVixOkBp NFLEWItKdmirYnn0bY9vKG:oIHLGS2YucW6mdXPl[EBk\WyuIIDyc4xq\mW{YYTpc44hf2m2aDDJR|UxKG:oIESuNFQh|ryP Mnr2NlE1PTB2NkO=
IM9 NYPrSIk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HxRlE3KGh? NUPoSFliSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gTW06KGOnbHzz NIP3UVkzOTR3MES2Ny=>
K562 NELMNYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;KeHZCOTZiaB?= MVjBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCNNU[yJINmdGy| M2TZdFIyPDVyNE[z
MDA-MB-231 NHXBXo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYexOkBp MVnBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPRFGtUWIuOjNzIHPlcIx{ NGPwOGQzOTR3MES2Ny=>
H460 NEnjZWJEgXSxdH;4bYMhSXO|YYm= NHfmeJk4OiCq MlnMTWM2OD1{Lkeg{txO MlLrNlE3OjF6OEC=
SMMC7721 NEn0cGtEgXSxdH;4bYMhSXO|YYm= NV;4OpREPzJiaB?= M3TMfWlEPTB;Nj60O{DPxE1? NUnBb3NoOjF4MkG4PFA>
WI38 MYLDfZRwfG:6aXOgRZN{[Xl? NHPIPVQ4OiCq MYPJR|UxRThwNU[g{txO MlTmNlE3OjF6OEC=
HEK293 NXjVcpFYU2mwYYPlJGF{e2G7 NUm5cGhTOTByIH7N M{PUT|EhcA>? MVTkc4V{KG6xdDDpcohq[mm2IG\FS2YucW6mdXPl[EBifXSxcHjvd5Bpd3K7bHH0bY9vKG:oIIT5do9{cW6nIEGxO|UhemW|aXT1[UBwdiCYRVfGVlIh\XiycnXzd4VlKGmwIFjFT|I6OyClZXzsdy=> NFqwW2ozOTh6NUK4Oy=>
HUVEC M{LZOGZ2dmO2aX;uJGF{e2G7 NWTjSWl1OSEQvF2= M{\MW|I1KGh? MVnBcpRq[W6paX;n[Y5q[yCjY4Tpeol1gSCjc4Pld5Nm\CCjczDk[YNz\WG|ZTDpckBXTUeILXnu[JVk\WRiY3XscEBucWe{YYTpc44> NUHsXZVOOjF7NkOzNFU>
HUVEC NVjOTJFUTnWwY4Tpc44hSXO|YYm= NUjUdXF7OSEQvF2= NHHaO|gyKGh? NUnhR|JMUW6qaXLpeIlwdiCxZjDFVmsheGixc4Doc5J6dGG2aX;uJIF1KFSqckKwNk9VgXJ{MESgbY4hXkWJRj3zeIlufWyjdHXkJGhWXkWF M{Hyc|IyQTZ|M{C1
HUVEC NEnkRlVHfW6ldHnvckBCe3OjeR?= NFTlPIoyKM7:TR?= M2i2V|EhcA>? MU\Jcohq[mm2aX;uJI9nKGWQT2OgdIhwe3Cqb4L5cIF1cW:wIHH0JHNmei1zMUeyJIlvKF[HR1[td5RqdXWuYYTl[EBJXV[HQx?= MY[yNVk3OzNyNR?=
HUVEC MmPwT4lv[XOnIFHzd4F6 NGOx[XEyKM7:TR?= M1nPflEhcA>? NF\EdVRKdmirYnn0bY9vKG:oIG\FS2ZTOiCyaH;zdIhwenmuYYTpc44h[XRidInyMVEyPzViaX6gWmVITi2|dHnteYxifGWmIFjVWmVE M13LflIyQTZ|M{C1
HUVEC NYe0bnlRTnWwY4Tpc44hSXO|YYm= MmPUNUDPxE1? MkK2NUBp MWXkc4V{KG6xdDDpcohq[mm2IFHLWEBxcG:|cHjvdplt[XSrb36gZZQhW2W{LUS3N{BqdiCYRVfGMZN1cW23bHH0[YQhUFWYRVO= M{S3blIyQTZ|M{C1
HL60 M3rXPGN6fG:2b4jpZ{BCe3OjeR?= NYnubG9qPTBizszN NGrEU2I1QCCq M4XieWROW09? NX\XdVlWUUN3ME2xOU42KM7:TR?= NV64SnYzOjJyMUmxPFg>
K562 NX7xSJpvS3m2b4TvfIlkKEG|c3H5 NGH3Tnc2OCEQvF2= MVq0PEBp MXHEUXNQ MWjJR|UxRTJzLkmg{txO MWKyNlAyQTF6OB?=
PC3 NV7aNXdoS3m2b4TvfIlkKEG|c3H5 MoCzOVAh|ryP NHzsNm01QCCq NGT5WYNFVVOR MlT6TWM2OD1{NT6xJO69VQ>? NV\FbI1wOjJyMUmxPFg>
SF-539 M171W2tqdmG|ZTDBd5NigQ>? NFP2SZg{OzNizszN MUG2NEBucW5? MXHJcohq[mm2aX;uJI9nKFCGR1\SZoV1[SC2eYLvd4lv\SCtaX7hd4Uh[WO2aY\peJkhcW5iUFTHSk1DSi2|dHnteYxifGWmIHj1cYFvKFOILUWzPUBk\WyuczD3bZRpKEmFNUCgc4YhOTJwMjFOwG0> M1qwV|IzOjB2N{Sx
HAEC MoHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4K3WlExOCEQvF2= MmXuO|IhcA>? MYfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiDRVOgZ4VtdHNiZYjwdoV{e2mwZzDWSWdHWiC5aYToJGlEPTBib3[gNE4yKM7:TR?= NEO3b|gzOjR2NE[3PS=>
HT-29 M{izOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zTVlExOCEQvF2= M{naV|czKGh? MoHyRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKVD2yPUBk\WyuczDlfJBz\XO|aX7nJHZGT0[UIIfpeIghUUN3MDDv[kAxNjN|IN88US=> NYTzfnVWOjJ2NES2O|k>
MV4-11 NEfUeoVEgXSxdH;4bYMhSXO|YYm= NEXLWHY4OiCq NUDKRpRkUUN3ME2wMlAxOyEQvF2= MXuyNlQ2OjVzOB?=
HepG2 NUX6dnBJS3m2b4TvfIlkKEG|c3H5 MUm0PEBp NUDkeohkUUN3ME2xN{4zPCEQvF2= Mn7jNlI1QDN4MEi=
PC9 M1LTbWN6fG:2b4jpZ{BCe3OjeR?= MmLVOFghcA>? MnzCTWM2OD1zMD65O{DPxE1? NVPhT2ZwOjJ2OEO2NFg>
CAKI-1 NI[0S4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVixNFAh|ryP MnrTOFghcA>? Mn3hSG1UVw>? NXfFNppvT0l3ME2wMlY{KM7:TR?= M2[ySFIzPTZyNkK3
EKVX NV\oZ|d7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHOU4tlOTByIN88US=> MX20PEBp NEDiUGRFVVOR NETiXlJIUTVyPUeuPUDPxE1? MWOyNlU3ODZ{Nx?=
MCF7 NHrXcIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2D0RlExOCEQvF2= M2n5S|Q5KGh? MXTEUXNQ MXjHTVUyRTJizszN MUOyNlU3ODZ{Nx?=
MDA-MB-435 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\neFExOCEQvF2= MVy0PEBp M{TFVGROW09? M4DrN2dKPTJ;MjFOwG0> MVKyNlU3ODZ{Nx?=
OVCAR3 NYGyT29WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU[xNFAh|ryP M1vDZ|Q5KGh? M2i5NWROW09? M32zWmdKPTN;Mz6yJO69VQ>? NVz0cGdwOjJ3NkC2Nlc>
SNB19 NUjq[ldPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXixNFAh|ryP NWK5W|hbPDhiaB?= MWDEUXNQ NG\Ie4FIUTV2PUGwJO69VQ>? NEPEW4IzOjV4ME[yOy=>
SW620 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvHNYQyODBizszN M{jlW|Q5KGh? MoK1SG1UVw>? NV:zeY1uT0l3NU2xMlMh|ryP MUGyNlU3ODZ{Nx?=
TK10 NICySo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jvcFExOCEQvF2= MYi0PEBp MWnEUXNQ Mnv6S2k2Pj14LkOg{txO NVvi[oQyOjJ3NkC2Nlc>
UACC257 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYW0TXlOOTByIN88US=> MUO0PEBp M2D5[mROW09? M2jldmdKPTd;NDFOwG0> MWOyNlU3ODZ{Nx?=
HAEC MXHDfZRwfG:6aXOgRZN{[Xl? MYWxNFAh|ryP NVnHVIROPzJiaB?= MWDEUXNQ NYns[YVXS3m2b4TvfIlkcXS7IHHnZYlve3RiVlXHSnIh\XiycnXzd4lv\yCKQVXDJJdqfGhiSVO1NEBw\iByLkGg{txO NVzRNmNHOjNzM{G1OFE>
HT-29 MnTRR5l1d3SxeHnjJGF{e2G7 MoL1NVAxKM7:TR?= MVG3NkBp NH;ZOnRFVVOR NIjlZldEgXSxdH;4bYNqfHliYXfhbY5{fCCYRVfGVkBmgHC{ZYPzbY5oKGi3bXHuJGhVNTJ7IHPlcIx{KHerdHigTWM2OCCxZjCwMlM{KM7:TR?= MlOwNlMyOzF3NEG=
HCT116 NInqVVRHfW6ldHnvckBCe3OjeR?= NGLCOXYzPCCq NHzTNmRFVVOR NHrYdotCdnSrbXnndoF1d3K7IHHjeIl3cXS7IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3XscEBucWe{YYTpc44> NYCy[GpbOjNzNUOyNFA>
HUVEC NEHYRpBHfW6ldHnvckBCe3OjeR?= NXTuXY9LOiEQvF2= NUPrdItHOThiaB?= MWLEUXNQ M2K0PWFvfGmjbnfpc4dmdmmlIHHjeIl3cXS7IHnuJGhWXkWFczD1coRmeiCqeYDvfIlkKGOxbnTpeIlwdiCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHS3YnWg[o9zdWG2aX;u M2n3O|I{OTV|MkCw
ACHN NVfYVHYzS3m2b4TvfIlkKEG|c3H5 M17MWlYh\A>? MWPJR|UxRTJwNTFOwG0> MYCyN|M3ODFyNB?=
A498 MUjDfZRwfG:6aXOgRZN{[Xl? NHfXWZUyODBizszN MXq3NkBp M13mUmROW09? M3rre2lEPTB;ND6zJO69VQ>? M1jlS|I{PDh7NkK2
HUVEC M2S4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETFSnQ{KM7:TR?= NX3Xc|lkOjRiaB?= NV\xdpVOTE2VTx?= MoHHRY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCYRVfGMYlv\HWlZXSgeJVj\SCob4LtZZRqd25id3n0bEBGSzVyIH;mJFAvPjR3IN88US=> NFfSUYozOzV6M{mxNS=>
HUVEC NULaXJZLU2mwYYPlJGF{e2G7 MknwNlAxKM7:TR?= NWXXbnNsTE2VTx?= NV\aVWNrUW6qaXLpeIlwdiCxZjDWSWdHWjJicHjvd5Bpd3K7bHH0bY9vKGmwIHfyc5d1cCCoYXP0c5Iue3SrbYXsZZRm\CCKVW\FRy=> M2rIWlI{PTh|OUGx
HUVEC NUjwOYptU2mwYYPlJGF{e2G7 MWKyNFAh|ryP NXi3S5p1TE2VTx?= MUfJcohq[mm2aX;uJI9nKF[HR1\SNUBxcG:|cHjvdplt[XSrb36gbY4h\3Kxd4ToJIZi[3Sxcj3zeIlufWyjdHXkJGhWXkWF NYm5PJpCOjN3OEO5NVE>
A549 M2PHdWN6fG:2b4jpZ{BCe3OjeR?= NXf3XHdMPzJiaB?= M4WwTmROW09? NV3MNGFnUUN3ME2yMlQ1KM7:TR?= NVj6e2oyOjN4MEK0OFE>
HCT116 MUTDfZRwfG:6aXOgRZN{[Xl? NFLOUFQ4OiCq M4GyUGROW09? NFvLUVlKSzVyPUSuO|Eh|ryP MXeyN|YxOjR2MR?=
MCF7 NXzMUZJ4S3m2b4TvfIlkKEG|c3H5 MoruO|IhcA>? MWHEUXNQ M2XLNWlEPTB;Nj6yPUDPxE1? NWjjSlVHOjN4MEK0OFE>
BGC NU\1NYU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV73PWFMPzJiaB?= NHjLZWZFVVOR MYHJR|UxRTRwN{ig{txO MlrQNlM6QTlyNEC=
BxPC3 M{GwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnRO|IhcA>? M2LFTmROW09? MkPoTWM2OD1|Lk[zJO69VQ>? MX2yN|k6QTB2MB?=
HT-29 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX[3NkBp NYnjeGRlTE2VTx?= M2DCTWlEPTB;MT60O{DPxE1? MVyyN|k6QTB2MB?=
T24 MlP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWS3NkBp M{jofGROW09? MmPsTWM2OD1{LkS0JO69VQ>? NFfkRVEzOzl7OUC0NC=>
4T1 MWfDfZRwfG:6aXOgRZN{[Xl? NXfHTYZWPzJiaB?= MXvEUXNQ NIO1S4ZKSzVyPUCuNFE3KM7:TR?= MUWyOFg6ODZ3Mh?=
MCF7 Mk\wR5l1d3SxeHnjJGF{e2G7 MnLFO|IhcA>? M{TvNWROW09? M4LRTGlEPTB;MD6wNlcyKM7:TR?= NWPZT4hIOjR6OUC2OVI>
MCF7 M1zsfWN6fG:2b4jpZ{BCe3OjeR?= M4nLU|czKGh? M{TlN2ROW09? MXLJR|UxRTBwMEK5N{DPxE1? NGiyPHozPDh7ME[1Ni=>
MDA-MB-231 NVnDeHk6S3m2b4TvfIlkKEG|c3H5 NEf3[mQ4OiCq NIjCO|NFVVOR NV3JO3BTUUN3ME2wMlAzOjNizszN NEHObmwzPDh7ME[1Ni=>
MDA-MB-435 M1vae2N6fG:2b4jpZ{BCe3OjeR?= MUO3NkBp NYXke4k4TE2VTx?= NEC1cZpKSzVyPUCuNFA6PyEQvF2= MmDDNlQ5QTB4NUK=
MDA-MB-468 NWTYXGcxS3m2b4TvfIlkKEG|c3H5 NVGyOYRuPzJiaB?= NW\Fe4lTTE2VTx?= MnO0TWM2OD1yLkCwOlEh|ryP MnW4NlQ5QTB4NUK=
A431 M1nW[GtqdmG|ZTDBd5NigQ>? NVHnU21MOTBizszN MknUNUBp NXy0e3o{TE2VTx?= M3LwXGlvcGmkaYTpc44hd2ZiRVfGVkB4cXSqIFnDOVAhd2ZiMD6xO|IyKM7:TR?= NEDMPVYzPDh7ME[1Ni=>
SH-SY5Y NET3bJBMcW6jc3WgRZN{[Xl? NWDnOXNyOTBizszN M1naNlEhcA>? MlHGSG1UVw>? M4TRTmlvcGmkaYTpc44hd2ZiUFTHSnJj\XSjIIfpeIghUUN3MDDv[kAxNjB6M{Gg{txO NF\FPY8zPDh7ME[1Ni=>
U251 NX\k[lhLU2mwYYPlJGF{e2G7 M3jZWVExKM7:TR?= NXLCNlhWOSCq NGnudI9FVVOR Mo\XTY5pcWKrdHnvckBw\iCYRVfGVlIhf2m2aDDJR|UxKG:oIECuNFE5QSEQvF2= MXKyOFg6ODZ3Mh?=
Bel7402 NWD3b3AyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{D2[FczKGh? NH7VNmRFVVOR NILw[GVKSzVyPUKuOlch|ryP NVfTNlg6OjR7MES5OlE>
HK2 Mmf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW[3NkBp MkDtSG1UVw>? M3rTRWlEPTB;NT64OUDPxE1? NYHUV2dROjR7MES5OlE>
LO2 MoixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TwXlczKGh? M{TnOGROW09? NIXBVGJKSzVyPUG5Mlk{KM7:TR?= NXruSmN5OjR7MES5OlE>
MV4-11 NXHkenBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHCflA1QCCq NGjsO45FVVOR NF\BNmtKSzVyPUCuNFA{KM7:TR?= MUeyOFkxPDl4MR?=
NCI-H3122 NXLhOmVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlj1O|IhcA>? MXXEUXNQ Mk\oTWM2OD1yLkizJO69VQ>? Ml3ONlQ6ODR7NkG=
NCI-H460 M4LNZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17oV|czKGh? NH:2cVRFVVOR M{T2VmlEPTB;ND6zNUDPxE1? NVXkNYdjOjR7MES5OlE>
NCI-H526 M1u1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfJO|IhcA>? NH\4UZhFVVOR MoHrTWM2OD1zLkCxJO69VQ>? NHjoVlgzPDlyNEm2NS=>
TT M4HIVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jv[|czKGh? NFTQWpFFVVOR M1vnV2lEPTB;MD6wOEDPxE1? NUPnc4h2OjR7MES5OlE>
EoL-1-cell NUHEdGRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3foSmlEPTB;MT62OEBxVQ>? MnzvV2FPT0WU
MV-4-11 MkjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\FTWM2OD1{N{KgdG0> NHLkeY1USU6JRWK=
NOS-1 M{PXSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTh[lNrUUN3ME2xOU4{KG6P NILOS2lUSU6JRWK=
CGTH-W-1 MnLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvXTWM2OD1|MD65OEBvVQ>? MoPQV2FPT0WU
MONO-MAC-6 NVHkZnFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTN|Lkigcm0> NIDsOW5USU6JRWK=
ALL-PO NHLFOIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLRbW1KSzVyPUe5Mlg6KG6P M4r3[HNCVkeHUh?=
NKM-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzvTWM2OD17OD61NkBvVQ>? MUjTRW5ITVJ?
KM12 NX:3NI82T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mni2TWM2OD1|NUCuNVQhdk1? MV7TRW5ITVJ?
TE-15 M4\MeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7zSo9mUUN3ME21NFcvPjFibl2= MkfXV2FPT0WU
697 NXXmSYJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml:1TWM2OD14MUSuNlUhdk1? MnXDV2FPT0WU
MOLT-16 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4i5SGlEPTB;NkOxMlMzKG6P NIfpPVBUSU6JRWK=
GB-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fxWGlEPTB;N{GwMlI{KG6P NUC0bm1XW0GQR1XS
TE-12 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRThyND61OUBvVQ>? MorvV2FPT0WU
ES6 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7KTWM2OD17OEGuNFYhdk1? NEXjXGZUSU6JRWK=
LC-2-ad NGPLfVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPZToY1UUN3ME2xMlEyPDB5IN88US=> Mm\GV2FPT0WU
BL-70 NF3lZ|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfIVFNOUUN3ME2xMlEyQDR4IN88US=> NI[xZoFUSU6JRWK=
ETK-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjBOZE2UUN3ME2xMlI5PThizszN M1r3e3NCVkeHUh?=
A4-Fuk Mn:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvqTWM2OD1zLkO0NVQyKM7:TR?= MXLTRW5ITVJ?
OCI-AML2 M3L1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlO5TWM2OD1zLkO2PFUyKM7:TR?= NH:1[25USU6JRWK=
SIG-M5 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXtTWM2OD1zLkO3NFA6KM7:TR?= NU\IXZpxW0GQR1XS
NCI-SNU-16 M1HDc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTFwNE[0PFYh|ryP M3TJSXNCVkeHUh?=
PSN1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGn2XVJKSzVyPUGuOVA3PzZizszN MXrTRW5ITVJ?
SR NXzJTlRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPocY5KUUN3ME2xMlU1PTd{IN88US=> MUfTRW5ITVJ?
A3-KAW M2Hxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\BXoZKSzVyPUGuOlI2PDZizszN NFTyRpVUSU6JRWK=
KS-1 Mn;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPuTWM2OD1zLk[5NlQ4KM7:TR?= MWrTRW5ITVJ?
CTV-1 M3jH[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTFwN{K3OVEh|ryP M{DIXHNCVkeHUh?=
LB1047-RCC M{nBe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTFwOEG2NlQh|ryP NH23S4tUSU6JRWK=
EMG-01 MnjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Xq[WlEPTB;MT64N|U3OyEQvF2= M4HnOXNCVkeHUh?=
TE-11 NX:4fXU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LsSmlEPTB;MT64N|k5PSEQvF2= M2fNWXNCVkeHUh?=
CMK NFrBfnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTFwOUW1NVch|ryP NHvqNndUSU6JRWK=
NB1 NYnG[nZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV70WXRjUUN3ME2xMlk3OTF5IN88US=> NGe3WFdUSU6JRWK=
HAL-01 M{fKfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3wfndKSzVyPUKuNFU6PDZizszN NFnlZXpUSU6JRWK=
DEL M4\WcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTJwMEi0PFIh|ryP MXfTRW5ITVJ?
RL95-2 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4m0VWlEPTB;Mj6xNVE{PyEQvF2= NYLVVYhHW0GQR1XS
KARPAS-299 M13aNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1[2UWlEPTB;Mj6xNVMyOyEQvF2= MUDTRW5ITVJ?
EW-16 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\HfGxKSzVyPUKuNVM2ODhizszN MkS0V2FPT0WU
RS4-11 NWnqfYRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIj2OYNKSzVyPUKuNVc6OjRizszN NECySXJUSU6JRWK=
BB30-HNC MlTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYGzSZhFUUN3ME2yMlIzOzd3IN88US=> MnLXV2FPT0WU
DOHH-2 MmHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPXTpBKSzVyPUKuN|M1OzFizszN MVjTRW5ITVJ?
RPMI-8402 NX3CdZVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPmUnNEUUN3ME2yMlM{PjF6IN88US=> NInxTppUSU6JRWK=
BV-173 NWH5[FU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPETWM2OD1{LkOzOlYh|ryP NXHnPHNFW0GQR1XS
TE-10 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTXTWM2OD1{LkO0N|g1KM7:TR?= MYPTRW5ITVJ?
TE-8 M4ThSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jB[WlEPTB;Mj6zO|A{QCEQvF2= NFS3[4hUSU6JRWK=
K052 M3\QNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4[yTmlEPTB;Mj60NFIxOiEQvF2= MXjTRW5ITVJ?
KARPAS-45 MlPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\ISGM4UUN3ME2yMlQ6PDR4IN88US=> NUPCdIlOW0GQR1XS
SK-NEP-1 NEXsZ2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFywNodKSzVyPUKuOlAzOzdizszN MnPuV2FPT0WU
KGN NYTKNm5WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rtUWlEPTB;Mj62NFM{QSEQvF2= M3\lNnNCVkeHUh?=
ML-2 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPoZ2V4UUN3ME2yMlY{PTF{IN88US=> M1TncHNCVkeHUh?=
LAMA-84 M2\Q[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoK2TWM2OD1{Lk[5OVQ2KM7:TR?= NVnXRoNCW0GQR1XS
LXF-289 NWe2fJJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTJwN{K5PFkh|ryP MXHTRW5ITVJ?
A101D M3e0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTJwN{izNFQh|ryP MkD1V2FPT0WU
KY821 Mn\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoX1TWM2OD1{Lke5O|U5KM7:TR?= NFfJNndUSU6JRWK=
ES4 NHP2WllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTxTWM2OD1{LkiwOlI5KM7:TR?= M{nmR3NCVkeHUh?=
SCC-3 NXjJSlI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rrdmlEPTB;Mj64Nlg6OSEQvF2= M1i0eHNCVkeHUh?=
NALM-6 Mli3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTJwOUC0O|Mh|ryP MVvTRW5ITVJ?
BL-41 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrqTWM2OD1{LkmxNlIzKM7:TR?= Mmf2V2FPT0WU
OPM-2 M2DKN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\qTWM2OD1|LkC1PVU1KM7:TR?= MnfXV2FPT0WU
SF126 M4jxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIn1PFFKSzVyPUOuNFYyQThizszN MV3TRW5ITVJ?
BE-13 M3zaTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HhWWlEPTB;Mz6yN|EyOSEQvF2= Mny0V2FPT0WU
SF268 M4PmVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\XTWM2OD1|LkOyPFY6KM7:TR?= MWLTRW5ITVJ?
MOLT-4 NIDReZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfMS3J4UUN3ME2zMlM6QDN6IN88US=> MnnMV2FPT0WU
PF-382 NWniOZBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nQfGlEPTB;Mz60OFU4KM7:TR?= MVnTRW5ITVJ?
HEL M3fZOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnLd2JKSzVyPUOuOFgxODVizszN MVnTRW5ITVJ?
RPMI-6666 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2m0bmlEPTB;Mz61OFE4OSEQvF2= MXHTRW5ITVJ?
QIMR-WIL M2X1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmiyTWM2OD1|Lk[zN|kyKM7:TR?= MnPLV2FPT0WU
ATN-1 M1HUS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrnSpVKSzVyPUOuOlcyOTRizszN M4PRe3NCVkeHUh?=
BB49-HNC M4LsPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTNwN{C1NFgh|ryP MV;TRW5ITVJ?
HCE-4 NX\PRlJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\hT|hKSzVyPUOuO|g3PDJizszN MkG0V2FPT0WU
SK-LMS-1 Mlr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXDTWM2OD1|LkizN|M5KM7:TR?= NYHmc|RlW0GQR1XS
MS-1 M2fhN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTNwOEO3O|gh|ryP M1\PU3NCVkeHUh?=
JAR M{HNb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTNwOUi4N|Ih|ryP NXnVZ2w1W0GQR1XS
KE-37 NWPiWodzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\DdnFKSzVyPUSuNFYyPThizszN NVPCNWt3W0GQR1XS
LB996-RCC NIjqRZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHO1eYFKSzVyPUSuNVIyPjhizszN M2XkV3NCVkeHUh?=
HH M1LDfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrBTnJLUUN3ME20MlIxQTF2IN88US=> MV3TRW5ITVJ?
HL-60 MmT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nCc2lEPTB;ND6yNVA3PSEQvF2= MkPsV2FPT0WU
HOP-62 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTGNINKSzVyPUSuN|M2OiEQvF2= NHrER3hUSU6JRWK=
NOMO-1 MmHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTRwM{O2PVkh|ryP M3HFcnNCVkeHUh?=
DU-4475 NYDQXnlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvNOVBKSzVyPUSuN|Y4OjlizszN MnHOV2FPT0WU
LC4-1 NHPvZmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPNNJFKSzVyPUSuN|gxPyEQvF2= M3XaR3NCVkeHUh?=
MC116 NVT5Wod{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHzTWM2OD12LkSzNFgyKM7:TR?= NFLaSWNUSU6JRWK=
SW982 NIfHfIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTlTZh{UUN3ME20MlU2OzB5IN88US=> MnPKV2FPT0WU
SK-N-DZ M{nSN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoD0TWM2OD12Lk[3NFk6KM7:TR?= MUTTRW5ITVJ?
EW-1 M3PqU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfYfG5KSzVyPUSuOlc6OTFizszN MYrTRW5ITVJ?
SU-DHL-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPwTWM2OD12LkiwNVc1KM7:TR?= MVvTRW5ITVJ?
L-363 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTRwOEC2NlEh|ryP MYHTRW5ITVJ?
OS-RC-2 Mmj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4T3SmlEPTB;ND64O|MyKM7:TR?= MmDsV2FPT0WU
HD-MY-Z M4nYWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTVwMUezNFEh|ryP NV[yO2lSW0GQR1XS
MHH-PREB-1 NFjK[|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlyxTWM2OD13LkOyN|EzKM7:TR?= NIrVUYxUSU6JRWK=
HC-1 MljsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTVwNEOyPVEh|ryP Mmj4V2FPT0WU
SK-MM-2 M3X0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjxSnBHUUN3ME21MlQ4QDJizszN M33lcnNCVkeHUh?=
SH-4 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLQe|NyUUN3ME21MlQ5OzdizszN MWjTRW5ITVJ?
MHH-CALL-2 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFX1dWlKSzVyPUWuO|Y4OTlizszN M3XGfHNCVkeHUh?=
KG-1 MnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTZwMEK4O|gh|ryP M4jIenNCVkeHUh?=
J-RT3-T3-5 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rpTmlEPTB;Nj6wO|kxQSEQvF2= M3PEcXNCVkeHUh?=
MMAC-SF NUPIepp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTZwMUC5OFkh|ryP Mn7zV2FPT0WU
IST-SL2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjDSWZKSzVyPU[uNVI2OTlizszN NGLIT5JUSU6JRWK=
SW954 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFj0N49KSzVyPU[uNlc2OTdizszN NYrCU|JyW0GQR1XS
HDLM-2 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfCSFRKSzVyPU[uN|IyODlizszN MUPTRW5ITVJ?
ST486 NVnaTYVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIX4ZWZKSzVyPU[uN|Q4OSEQvF2= NV;wVpN4W0GQR1XS
DG-75 M4DU[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnRWpVKSzVyPU[uOFMxPjlizszN MV3TRW5ITVJ?
EW-3 NF35bWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTZwNEOyNFch|ryP NIXJUmlUSU6JRWK=
8-MG-BA M3HJV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnL5TWM2OD14LkWxOVA4KM7:TR?= NUT4VIJ1W0GQR1XS
GT3TKB Mn;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjoSWFKSzVyPU[uOlA4PjNizszN MkewV2FPT0WU
KU812 M1T4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWO4ToNnUUN3ME22MlY6PDJizszN NF\lTYxUSU6JRWK=
CESS NES1T3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTdwMUC0N|gh|ryP NUfycHNDW0GQR1XS
BC-1 M2\GSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnaR|NKSzVyPUeuNlQ5OTJizszN MmXKV2FPT0WU
MZ1-PC NGjlO3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvDUmpFUUN3ME23MlMxOzh7IN88US=> NV;XWINHW0GQR1XS
NCI-H82 MmLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTdwM{e4OUDPxE1? MVfTRW5ITVJ?
NCI-H1355 NYW2N2xGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmj1TWM2OD15LkS1PFA1KM7:TR?= NXS5cHJ7W0GQR1XS
RPMI-8226 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTdwNUC3N|kh|ryP NFnZPJpUSU6JRWK=
ARH-77 M4fKNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTdwNUO1PVch|ryP MYXTRW5ITVJ?
MN-60 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nNdWlEPTB;Nz61OFA5QCEQvF2= NEC0SZFUSU6JRWK=
IMR-5 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXGTWduUUN3ME23NFU1QDd4IN88US=> NI\q[5FUSU6JRWK=
KARPAS-422 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorKTWM2OD15LkW3NlA3KM7:TR?= MXPTRW5ITVJ?
CA46 NHy4XW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXwdo9KSzVyPUeuOVgxOTJizszN NH\1V2RUSU6JRWK=
SJSA-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTdwNk[wOlEh|ryP NXzlc5k3W0GQR1XS
no-11 NYH1dWg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HPUGlEPTB;Nz63O|U2PyEQvF2= NWDPUWVPW0GQR1XS
IST-SL1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRThwMEK0NVch|ryP MYDTRW5ITVJ?
NCI-H209 NHfye|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRThwMUG2OVIh|ryP NYrn[pZYW0GQR1XS
TALL-1 M1PBXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEj5WGhKSzVyPUiuNVg{QDRizszN NXLCUmp1W0GQR1XS
KMOE-2 NIHM[XZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXxT4NPUUN3ME24MlE6PDJizszN MlrHV2FPT0WU
HCC1599 MortS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnOzTWM2OD16LkG5PVg4KM7:TR?= MUPTRW5ITVJ?
CI-1 NX;1SnhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRThwMkC0NVEh|ryP M4G2fnNCVkeHUh?=
NCI-H1304 NUnt[mxYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRThwMkC2OlEh|ryP MnPMV2FPT0WU
Daudi M1zLXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmntTWM2OD16LkKzOVQ3KM7:TR?= MWjTRW5ITVJ?
CPC-N MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRThwMkmxPVkh|ryP NWjOXo1rW0GQR1XS
MC-CAR NHz3UnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrwblRKSzVyPUiuN|M2QCEQvF2= NYDyRmN{W0GQR1XS
SW872 NGrBUGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIKzc|FKSzVyPUiuN|Q4PThizszN MX7TRW5ITVJ?
OVCAR-4 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3y5TmlEPTB;OD61NFM2OSEQvF2= M{DsR3NCVkeHUh?=
OCUB-M NIHJOJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3JO|JKSzVyPUiuOVY2ODhizszN MlzRV2FPT0WU
SK-PN-DW MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRThwNkC5PFUh|ryP M3rJWnNCVkeHUh?=
NCCIT MmfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPnZ4YxUUN3ME24MlcyPzR3IN88US=> NITXO3pUSU6JRWK=
NCI-H1648 MnHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTlwMUO4N|Qh|ryP MmTIV2FPT0WU
COR-L279 M1nLUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LEfWlEPTB;OT6zPVA6KM7:TR?= MWXTRW5ITVJ?
LS-123 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjxc3hIUUN3ME25MlY5OTZzIN88US=> NUf3b3lHW0GQR1XS
LP-1 M1XD[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrGfJpRUUN3ME25Mlc5ODh|IN88US=> NHrJbIRUSU6JRWK=
NB13 M33Scmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DnTGlEPTB;OT63PVk6PCEQvF2= M4HsNHNCVkeHUh?=
ONS-76 NXW1XpJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnSSnNKSzVyPUmuPFExOTZizszN NH\ObmFUSU6JRWK=
VA-ES-BJ M4PyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LBcGlEPTB;OT65PVk{OyEQvF2= MYnTRW5ITVJ?
GR-ST MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jsNGlEPTB;MUCuNlIxPyEQvF2= NUfWOms5W0GQR1XS
ES1 NUWzcppLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILzTWZKSzVyPUGwMlI6QDRizszN M{XjPXNCVkeHUh?=
NB14 NHK2[VFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTFyLkmyO|ch|ryP NG[0T2JUSU6JRWK=
Ramos-2G6-4C10 NHHrdIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHBTWM2OD1zMT6yOlUh|ryP MXHTRW5ITVJ?
RXF393 M{SzOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTyTWM2OD1zMT60PFM1KM7:TR?= MnnZV2FPT0WU
NCI-H2107 Mof3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTFzLkW5PFQh|ryP Ml\wV2FPT0WU
K562 MnXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnmZ41KSzVyPUGxMlg4ODJizszN NXTJW5lGW0GQR1XS
LOUCY NVHscoRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTFzLkm4O|Uh|ryP MmiwV2FPT0WU
TGBC1TKB NHnBPZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPvR5NKUUN3ME2xNk4xODJizszN NXPZTFBxW0GQR1XS
COLO-320-HSR MljoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1KxRmlEPTB;MUKuNVU3PSEQvF2= NWrpenNvW0GQR1XS
K5 NVnxfVNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrPbphEUUN3ME2xNk4zQTh3IN88US=> NHmxPXRUSU6JRWK=
BC-3 Ml36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTF{LkS2OVEh|ryP MXfTRW5ITVJ?
REH NF\RXnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTF{Lk[0PVgh|ryP MlryV2FPT0WU
NEC8 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rPTWlEPTB;MUKuOlg5PyEQvF2= MorKV2FPT0WU
IST-MEL1 MnnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzWOGpKSzVyPUGyMlg3QTRizszN NH;kSXVUSU6JRWK=
NCI-H128 MnjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{D0cmlEPTB;MUOuNFczOyEQvF2= M1GyZXNCVkeHUh?=
NCI-H1694 MlX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkToTWM2OD1zMz6xNVQ1KM7:TR?= M1jETHNCVkeHUh?=
TGW MmTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTF|LkOyO|Yh|ryP MoS2V2FPT0WU
NCI-SNU-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnncoh5UUN3ME2xN{4{PDVizszN NYHmW24xW0GQR1XS
IST-MES1 M3y1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXzeHRGUUN3ME2xN{43PzJ7IN88US=> NVPUW2lvW0GQR1XS
CTB-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXKyXXBLUUN3ME2xN{44Ojl2IN88US=> M{PsNXNCVkeHUh?=
HUTU-80 MorTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXKTWM2OD1zMz63OVc{KM7:TR?= MnX3V2FPT0WU
LAN-6 NGW5bI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3G3T2lEPTB;MUSuNlQ2PyEQvF2= M160[XNCVkeHUh?=
KP-N-YS NWKxb3FiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlf1TWM2OD1zND6yPFk1KM7:TR?= NU\ocGZVW0GQR1XS
CCRF-CEM NVPFXJFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;KW4cyUUN3ME2xOE41OTZ7IN88US=> NHHWR5VUSU6JRWK=
NCI-H1770 MoKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{j5ZWlEPTB;MUSuOVM3QSEQvF2= MUHTRW5ITVJ?
MZ2-MEL M37kNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4H2TGlEPTB;MUWuNlI2OSEQvF2= NHTSeXFUSU6JRWK=
COR-L88 NHvmbm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrvUo5KSzVyPUG2MlAxOTJizszN MV\TRW5ITVJ?
LOXIMVI MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjVdo9KSzVyPUG2MlI2PiEQvF2= MXXTRW5ITVJ?
KALS-1 NIT3epdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULndXd3UUN3ME2xOk42QTNzIN88US=> M2TNOnNCVkeHUh?=
D-283MED M1jPOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHEOFVCUUN3ME2xOk45PDh7IN88US=> NHfFdHNUSU6JRWK=
NCI-H719 NUTyZmdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M32yOmlEPTB;MU[uPVE3OSEQvF2= NXS2R4tnW0GQR1XS
MLMA MkfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3noXGlEPTB;MU[uPVkxPyEQvF2= M3q5dHNCVkeHUh?=
EVSA-T MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXvbZFKSzVyPUG3MlA1QDVizszN M3y3OXNCVkeHUh?=
SK-N-FI MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTF5Lk[5NVMh|ryP NXfM[YM2W0GQR1XS
NTERA-S-cl-D1 M3vobmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1z0UWlEPTB;MUeuPFU4OiEQvF2= MmLTV2FPT0WU
NCI-H1882 NXz4WG1PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTF5Lkm4N|Qh|ryP NHXCUWlUSU6JRWK=
A704 M3rPVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGS1fVdKSzVyPUG3Mlk6ODRizszN MnKyV2FPT0WU
L-428 Mln1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTF6LkCxOVEh|ryP NY\OW2RZW0GQR1XS
HCC1187 MlfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTF6LkCxPFch|ryP NWjV[I93W0GQR1XS
NCI-H1581 MnjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljNTWM2OD1zOD6wPFY3KM7:TR?= NH:3XnJUSU6JRWK=
BB65-RCC MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTF6LkSxOlIh|ryP NITwdHdUSU6JRWK=
EM-2 Mo\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTJTWM2OD1zOD61OlczKM7:TR?= NHfKU5JUSU6JRWK=
Raji NWLw[41ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHOx[2tKSzVyPUG5Mlk2PjVizszN MmPhV2FPT0WU
TE-1 MmjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzlTWM2OD1{MD60NVA1KM7:TR?= MXrTRW5ITVJ?
SW962 M1zMNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NES5NJJKSzVyPUKwMlQzQTNizszN MUjTRW5ITVJ?
MHH-NB-11 M3S4V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTJyLkW1NlEh|ryP MkTjV2FPT0WU
no-10 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfHNmlKSzVyPUKxMlAzPjRizszN Ml70V2FPT0WU
GDM-1 MlHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTJzLkm0NVQh|ryP M1fGVXNCVkeHUh?=
KMS-12-PE MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIro[IhKSzVyPUKyMlI4PCEQvF2= M4\5SXNCVkeHUh?=
NCI-H510A NWfqR|RlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlGwTWM2OD1{ND6xNlc5KM7:TR?= NGj0XYNUSU6JRWK=
ES5 MoD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTJ2LkezOFkh|ryP M4X2WXNCVkeHUh?=
JiyoyeP-2003 MnWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\hPWlEPTB;Mk[uNlc1OiEQvF2= M2PEUHNCVkeHUh?=
NMC-G1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTJ5LkG4NlIh|ryP NELrc3lUSU6JRWK=
NCI-H446 M{DXeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjhTWM2OD1{Nz60PVQ3KM7:TR?= MVrTRW5ITVJ?
NB7 NY\WXpVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTJ5LkmyNlkh|ryP MW\TRW5ITVJ?
A388 NILJSZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXwOWNMUUN3ME2yPE4xODd2IN88US=> Ml\VV2FPT0WU
JVM-2 NF\UdYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfnXGhKSzVyPUK4MlI5QThizszN NVTwZ5NYW0GQR1XS
HT-144 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTJ6Lk[5JO69VQ>? NF3MR|NUSU6JRWK=
NCI-H747 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXJTnlJUUN3ME2yPE46OTl3IN88US=> MVTTRW5ITVJ?
NCI-H1650 M2nOeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\3emlEPTB;MkmuNFE4PiEQvF2= MVHTRW5ITVJ?
EB-3 NYL4fYc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWi2XHhOUUN3ME2yPU42OzB7IN88US=> NGriWWhUSU6JRWK=
KLE NYLac5NVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nITWlEPTB;MkmuOlE6KM7:TR?= MWXTRW5ITVJ?
TK10 M1rS[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\qO2pKSzVyPUOwMlEzPiEQvF2= M4LMW3NCVkeHUh?=
COLO-668 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPjTWM2OD1|MD63PVIh|ryP MVTTRW5ITVJ?
NCI-H23 NXHDb45pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXEfohQUUN3ME2zNU4yODZ|IN88US=> NYX3XItiW0GQR1XS
GOTO NGfKcJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2P2SGlEPTB;M{GuOlA5PSEQvF2= MXfTRW5ITVJ?
MSTO-211H M1rvWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fiNmlEPTB;M{GuPFY4QCEQvF2= NVK0W2ZLW0GQR1XS
LB831-BLC NFPWUYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzuTWM2OD1|Mj6zPFQ{KM7:TR?= MYjTRW5ITVJ?
SCH MlPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLPZm1OUUN3ME2zNk45PDh3IN88US=> MnK0V2FPT0WU
EHEB Mn20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;3S2lEPTB;M{SuNVE6OyEQvF2= NHfxb2tUSU6JRWK=
U-266 M4TZXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn65TWM2OD1|ND6yO|gyKM7:TR?= NIPReHZUSU6JRWK=
EW-11 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jWe2lEPTB;M{SuOFczPSEQvF2= M1nhWXNCVkeHUh?=
TE-9 NWjKSmgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4m1XWlEPTB;M{euNFQxOSEQvF2= NGT3[GxUSU6JRWK=
ES3 NUTkeot6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnjTWM2OD1|Nz61NFA1KM7:TR?= M4rlN3NCVkeHUh?=
NCI-H2141 MlfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHycIhpUUN3ME2zPE4xQDR|IN88US=> MkCyV2FPT0WU
MPP-89 NYXaV3ZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zGNWlEPTB;NEKuNFU5PiEQvF2= NH7zN|dUSU6JRWK=
SK-MEL-2 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7V[GdKSzVyPUSyMlY1ODVizszN NWXRXmlzW0GQR1XS
LC-1F M{HZXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4O2XGlEPTB;NEOuN|Y5OiEQvF2= NXTX[otNW0GQR1XS
NH-12 MnvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HHVGlEPTB;NEOuPVM2QSEQvF2= MXTTRW5ITVJ?
RKO MlraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknwTWM2OD12ND6xNlUzKM7:TR?= Mof0V2FPT0WU
KM-H2 M2SySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWSydFVRUUN3ME20OE46PTd5IN88US=> Mm\oV2FPT0WU
SK-UT-1 M1Hs[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PEVGlEPTB;NEmuPFgzPSEQvF2= MVfTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT / AKT / p-ERK / ERK; 

PubMed: 24759734     


Effect of 72 h treatment with sunitinib on SH-SY5Y, SK N BE(2), SK-N-AS and IMR-32 NB cell lines analyzed by Western blot with pSer473Akt, Akt, pThr202/Thr204 Erk1/2 and Erk1/2 antibodies. β-actin was used as a loading control.

p-GSK3β / GSK3β / MYCN ; 

PubMed: 24759734     


Effect of sunitinib on GSK3β phosphorylation and on MYCN total protein in MYCN amplified NB cell lines.

p-STAT3 / STAT3 / p-Src / Src / p-AKT / AKT / p-ERK / ERK ; 

PubMed: 19244102     


Sunitinib reduced Stat3 and Src activity, with no dramatic reduction of AKT, MAPK and JAK signaling in 786-O cells. Tumor cells were treated with sunitinib at indicated concentrations for 2 h (left panels) or 24 h (right panels). Total cell lysates were prepared and western blots were performed using relevant antibodies to detect total protein levels, with β-actin used as the loading control.

24759734 19244102
Growth inhibition assay
Cell viability; 

PubMed: 24369536     


Isolated effects of sunitinib malate on urinary bladder-cancer cell lines viability, assessed by using the MTT assay. The data shown and bars represent the mean values ± SD (SD: standard deviation). *P < 0.05 versus untreated cells.

24369536
In vivo Consistent with the substantial and selective inhibition of VEGFR2 or PDGFR phosphorylation and signaling in vivo, Sunitinib (20-80 mg/kg/day) exhibits broad and potent dose-dependent anti-tumor activity against a variety of tumor xenograft models including HT-29, A431, Colo205, H-460, SF763T, C6, A375, or MDA-MB-435. Sunitinib dosing at 80 mg/kg/day for 21 days leads to complete tumor regression in six of eight mice, without tumor re-growing during a 110-day observation period after the end of treatment. Second round of treatment with Sunitinib remains efficacious against tumors that are not fully regressed during the first round of treatment. Sunitinib treatment results in significant decrease in tumor MVD, with ~40% reduction in SF763T glioma tumors. SU11248 treatment results in a complete inhibition of additional tumor growth of luciferase-expressing PC-3M xenografts, despite no reduction in tumor size. [2] Sunitinib treatment (20 mg/kg/day) dramatically suppresses the growth subcutaneous MV4;11 (FLT3-ITD) xenografts and prolongs survival in the FLT3-ITD bone marrow engraftment model. [3]

Protocol

Kinase Assay:[1]
- Collapse

Biochemical Tyrosine Kinase Assays:

IC50 values for Sunitinib against VEGFR2 (Flk-1) and PDGFRβ are determined using glutathione S-transferasefusion proteins containing the complete cytoplasmic domain of the RTK. Biochemical tyrosine kinase assays to quantitate the trans-phosphorylation activity of VEGFR2 (Flk-1) and PDGFRβ are performed in 96-well microtiter plates precoated (20 μg/well in PBS; incubated overnight at 4 °C) with the peptide substrate poly-Glu,Tyr (4:1). Excess protein binding sites are blocked with the addition of 1-5% (w/v) BSA in PBS. Purified GST-fusion proteins are produced in baculovirus-infected insect cells. GST-VEGFR2 and GST-PDGFRβ are then added to the microtiter wells in 2 × concentration kinase dilution buffer consisting of 100 mM HEPES, 50 mM NaCl, 40 μM NaVO4, and 0.02% (w/v) BSA. The final enzyme concentration for GST-VEGFR2 or GST-PDGFRβ is 50 ng/mL. Twenty-five μL of diluted Sunitinib are subsequently added to each reaction well to produce a range of inhibitor concentrations appropriate for each enzyme. The kinase reaction is initiated by the addition of different concentrations of ATP in a solution of MnCl2 so that the final ATP concentrations spanned the Km for the enzyme, and the final concentration of MnCl2 is 10 mM. The plates are incubated for 5-15 minutes at room temperature before stopping the reaction with the addition of EDTA. The plates are then washed three times with TBST. Rabbit polyclonal antiphosphotyrosine antisera are added to the wells at a 1:10,000 dilution in TBST containing 0.5% (w/v) BSA, 0.025% (w/v) nonfat dry milk, and 100 μM NaVO4 and incubated for 1 hour at 37 °C. The plates are then washed three times with TBST, followed by the addition of goat antirabbit antisera conjugated with horseradish peroxidase (1:10,000 dilution in TBST). The plates are incubated for 1 hour at 37 °C and then washed three times with TBST. The amount of phosphotyrosine in each well is quantitated after the addition of 2,2′-azino-di-[3-ethylbenzthiazoline sulfonate] as substrate.
Cell Research:[3]
- Collapse
  • Cell lines: RS4;11, MV4;11, and OC1-AML5
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 24 and 48 hours
  • Method: Cells are starved overnight in medium containing 0.1% FBS prior to addition of Sunitinib and FL (50 ng/mL; FLT3-WT cells only). Proliferation is measured after 48 hours of culture using the Alamar Blue assay or trypan blue cell viability assays. Apoptosis is measured 24 hours after Sunitinib addition by Western blotting to detect cleavage of poly (ADP-ribose) polymerase (PARP) or levels of caspase-3.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: Female nu/nu mice implanted s.c. with HT-29, A431, Colo205, H-460, SF763T, C6, A375, or MDA-MB-435, and male nu/nu mice bearing luciferase-expressing PC-3M tumors
  • Dosages: ~80 mg/kg
  • Administration: Orally once daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 15 mg/mL (28.16 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 532.56
Formula

C22H27FN4O2.C4H6O5

CAS No. 341031-54-7
Storage powder
in solvent
Synonyms N/A
Smiles CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C.C(C(C(=O)O)O)C(=O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03916458 Recruiting -- Carcinoma Renal Cell Pfizer January 21 2020 --
NCT04115189 Active not recruiting Drug: Sunitinib Metastatic Renal Cell Carcinoma ( mRCC) Pfizer December 13 2019 --
NCT04033991 Active not recruiting Drug: Sunitinib|Drug: Axitinib Carcinoma|Renal Cell Pfizer September 27 2019 --
NCT03900793 Recruiting Drug: Losartan|Drug: Sunitinib Osteosarcoma University of Colorado Denver|National Cancer Institute (NCI) August 22 2019 Phase 1
NCT03846128 Not yet recruiting Biological: blood sample Metastatic Kidney Cancer University Hospital Rouen August 2019 --
NCT03905889 Recruiting Drug: Abemaciclib|Drug: Sunitinib Renal Cell Carcinoma Metastatic Milton S. Hershey Medical Center|Eli Lilly and Company June 5 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I was wondering that the compound is in its cis or trans form?

  • Answer:

    S1042 Sunitinib Malate is Z form.

  • Question 2:

    What is the difference between Sunitinib Malate(S1042) and Sunitinib(S7781)?

  • Answer:

    S1042 is the Malate salt form of Sunitinib. The biological activities of these two compounds are the same but the solubility of these two compounds in aqueous solvent are different.

PDGFR Signaling Pathway Map

PDGFR Inhibitors with Unique Features

Related PDGFR Products

Tags: buy Sunitinib Malate | Sunitinib Malate supplier | purchase Sunitinib Malate | Sunitinib Malate cost | Sunitinib Malate manufacturer | order Sunitinib Malate | Sunitinib Malate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID